The Champalimaud Foundation today announced the acquisition of a portfolio of T-cell receptor (TCR) programs, platform technologies, and associated assets from Medigene Immunotherapies GmbH, together with the execution of an exclusive license agreement with Helmholtz Munich for key chimeric co-stimulatory receptor technologies.

Offer Description

Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for a Operations Unit Officer fellow to join our team. 

Champalimaud Research (CR) has an open position for an Operations Unit Officer, to work in a professional, dynamic and diverse work environment at the Champalimaud Centre for the Unknown.

Caring for patients is one of the Champalimaud Foundation’s core purposes, and the Radiotherapy Service supports that mission every day. 

In a highly controlled environment, precise doses of radiation are targeted to treat different types of cancer. 

Behind this precision is a dedicated team of specialised doctors, physicists, nurses and technicians, working together to ensure each treatment is both safe and effective.

Every detail matters. Every decision is guided by expertise, responsibility and care.

A synergy in advanced therapies

Signed in Rome on 28 April, the agreement combines the Champalimaud Foundation’s expertise in adult oncology with Bambino Gesù’s recognised leadership in paediatric oncology and cell therapies. This synergy strengthens the link between research and clinical practice throughout the translational medicine pathway.

The symposium will bring together national and international experts to explore the dynamic evolution of the field, with a special focus on the close collaboration between radiology and surgery.

Diagnostic and interventional radiology are currently undergoing remarkable transformation. New imaging methodologies are redefining precision and diagnostic capability, achieving unprecedented levels of accuracy and clinical impact. Innovations such as photon-counting CT technology and ultra-fast MRI protocols are rapidly expanding the horizons of medical imaging.

Could radiotherapy become the standard for lung cancer treatment? Could Artificial Intelligence (AI) help oncologists in treatment selection? Should many more resources be devoted to prevention, namely populational screening for this cancer? 

Cancer experts gathered at the Champalimaud Foundation (CF), in Lisbon, for the third edition of the Lung Cancer Fight Club, to debate for a day on these and other issues.

The Champalimaud Foundation (CF) was one of four institutions, together with more than 20 individuals (health and pharmaceutical specialists, clinicians, nurses, health managers, etc.) to receive this year the Ministry of Health’s Medal for Distinguished Service - Gold Class, rewarding the work they developed for the benefit of Health in Portugal. The medals were awarded on April 7th, during a ceremony marking World Health Day which took place at the Champalimaud Foundation, in Lisbon.

This procedure was done within the framework of the newly launched Programme for Minimally Invasive Robotic and Endoscopic Breast Surgery, an initiative developed by the Champalimaud Foundation as part of the surgical treatment options offered to selected breast cancer patients, representing a significant advancement in surgical innovation and patient-centred care.